Clinical Trial Update: Neoadjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant trial of pyrotinib in HER2-positive breast cancer is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Pyrotinib (pyrotinib)

Snippet

Sponsor: RenJi Hospital | Conditions: Breast Cancer Female | Phase 2 | Status: ACTIVE_NOT_RECRUITING